Canadian Blood Service: SARS-CoV-2 Seroprevalence Study
Networks
-
Datasets
-
Variables
-
The main objectives of the study are to:
* monitor SARS-CoV-2 seroprevalence on a monthly basis,
* compare seroprevalence by demographic and geographic variables, and
* monitor vaccine uptake.
- Start Year
- 2020
Visit CBS
| Investigators | Contacts |
|---|---|
|
|
Design
- Study design
- Cross-sectional
- Follow Up
- At phase I participants were seen from May 9, 2020 until July 21, 2020. As of August 2020, only samples from the last 2 weeks of each month are tested. As of December 2020, all samples are sampled once again. Additional phases of testing are anticipated.
Recruitment
- Recruitment Target
-
- Individuals
Number of Participants
- Number of Participants
- No Limit
- Number of Participants with Biological Samples
Access
Availability of data and biosamples
| Possible Access to Data | |
| Possible Access to Biosamples | |
| Other |
Timeline
CBS population
The population consists of apparently healthy blood donors from across Canada in all larger cities and most urban areas, who are at least 17 years of age.
Selection Criteria
- Minimum age
-
17
- Newborns
- Twins
- Countries
-
- Canada
- Territory
- Ethnic Origin
-
- Health Status
-
- In good health
- Other Criteria
- Must meet all criteria to donate blood.
Recruitment
- Sources of recruitment
-
- Specific population
- Specific Population
-
- Other specific population : Blood donors
- Supplementary Information
-
Participants were regular blood donors from a combination of fixed and mobile sites in all larger cities and most urban areas. This project uses retention samples from blood donations that would normally be discarded.
Number of Participants
- Number of Participants
- No Limit
- Number of Participants with Biological Samples
Data Collection Event
Demographic data including age, sex, city, province, region, self-reported ethnicity, whether participants are first/repeated blood donors, date of donation and Forward Sortation Area Code (FSA) was extracted from the donor database for donors tested for SARS-CoV-2 antibodies.
SARS-CoV-2 antibody testing was done. All plasma samples were tested using the Abbott Architect SARS-CoV-2 IgG assay (chemiluminescent microparticle immunoassay (CMIA)) which utilizes the nucleocapsid antigen.
Data was collected from health databases at the time of donation primarily for the purpose of assessing eligibility.
- Start Date
-
2020-05
- Data sources
-
- Questionnaires
- Biosamples
- Administrative databases
- Data sources - Biosamples
-
- Blood
- Data sources - Administrative databases
-
- Health databases
Classifications
- Socio-demographic and economic characteristics
- Lifestyle and behaviours
- Birth, pregnancy and reproductive health history
- Perception of health, quality of life, development and functional limitations
- Diseases
- Symptoms and signs
- Medication and supplements
- Non-pharmacological interventions
- Health and community care services utilization
- Death
- Physical measures and assessments
- Laboratory measures
- Cognition, personality and psychological measures and assessments
- Life events, life plans, beliefs and values
- Preschool, school and work life
- Social environment and relationships
- Physical environment
- Administrative information
Socio-demographic and economic characteristics
Age/birthdate
Sex/gender
Residence
Ethnicity, race and religion
Non-pharmacological interventions
Other and unspecified non-pharmacological interventions
Laboratory measures
Virology
Administrative information
Date and time-related information